

On page 26, line 18: replace "Streamline" with — STREAMLINE—.

After the claims, insert the attached "Abstract."

In the claims:

Please amend the claims as follows:

Please cancel claims 2-4 and claims 6-8 without prejudice.

1. (Amended) A [modified] polymer-modified monovalent antibody fragment comprising [a monovalent antibody fragment] an antigen-binding fragment and at least one polymer molecule in covalent linkage characterized in that each cysteine residue located in the [antibody] antigen-binding fragment outside of the variable region domain [of the fragment] is either covalently linked through its sulphur atom to a polymer molecule or is in disulfide linkage with a second cysteine residue located in the antigen-binding fragment [provided that at least one of said cysteine residues is linked to a polymer molecule.];

wherein said antigen-binding fragment is covalently linked to one, two or three polymer molecules through one, two or three cysteine residues located in the antigen-binding fragment outside its variable domain;

and wherein said polymer is an optionally substituted, straight or branched chain polymer selected from the group consisting of poly(ethylene glycol), poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol) and derivatives thereof.

5. (Amended) An antibody fragment according to [Claim 4] claim 1 wherein the polymer is selected from the group consisting of methoxy(polyethylene glycol) and derivatives